

David Z Qian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11276054/publications.pdf>

Version: 2024-02-01

29
papers

3,331
citations

257450

24
h-index

526287

27
g-index

30
all docs

30
docs citations

30
times ranked

5503
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Digoxin and other cardiac glycosides inhibit HIF-1 α synthesis and block tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19579-19586. | 7.1 | 568 |
| 2 | Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17910-17915. | 7.1 | 426 |
| 3 | Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1 α . Cancer Research, 2006, 66, 8814-8821. | 0.9 | 292 |
| 4 | Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589. Clinical Cancer Research, 2006, 12, 634-642. | 7.0 | 264 |
| 5 | The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584. Cancer Research, 2004, 64, 6626-6634. | 0.9 | 229 |
| 6 | HDAC4 Protein Regulates HIF1 α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia. Journal of Biological Chemistry, 2011, 286, 38095-38102. | 3.4 | 169 |
| 7 | HIF1 α Protein Stability Is Increased by Acetylation at Lysine 709. Journal of Biological Chemistry, 2012, 287, 35496-35505. | 3.4 | 123 |
| 8 | Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription with Efficacious in Vivo Anticancer Activity. Journal of Medicinal Chemistry, 2015, 58, 5075-5087. | 6.4 | 120 |
| 9 | Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model. Clinical Cancer Research, 2007, 13, 4201-4208. | 7.0 | 111 |
| 10 | ID1 Enhances Docetaxel Cytotoxicity in Prostate Cancer Cells through Inhibition of p21. Cancer Research, 2010, 70, 3239-3248. | 0.9 | 109 |
| 11 | Platelets Take Up the Monoclonal Antibody Bevacizumab. Clinical Cancer Research, 2007, 13, 5341-5347. | 7.0 | 105 |
| 12 | Combination Strategy Targeting the Hypoxia Inducible Factor-1 α with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors. Clinical Cancer Research, 2008, 14, 3589-3597. | 7.0 | 105 |
| 13 | CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate, 2010, 70, 433-442. | 2.3 | 98 |
| 14 | Epigenetic Modulation of Retinoic Acid Receptor β 2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma. Clinical Cancer Research, 2005, 11, 3535-3542. | 7.0 | 76 |
| 15 | Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Molecular Cancer Therapeutics, 2007, 6, 70-81. | 4.1 | 74 |
| 16 | Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate, 2007, 67, 1182-1193. | 2.3 | 65 |
| 17 | The Iroquois Homeobox Gene 5 Is Regulated by 1,25-Dihydroxyvitamin D3 in Human Prostate Cancer and Regulates Apoptosis and the Cell Cycle in LNCaP Prostate Cancer Cells. Clinical Cancer Research, 2008, 14, 3562-3570. | 7.0 | 55 |
| 18 | A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma. Science Translational Medicine, 2011, 3, 85ra47. | 12.4 | 54 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism. <i>Prostate</i> , 2013, 73, 1028-1037. | 2.3 | 52 |
| 20 | Molecular Crosstalk Between MYC and HIF in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 590576. | 3.7 | 50 |
| 21 | Systemic Inhibition of CREB is Well-tolerated in vivo. <i>Scientific Reports</i> , 2016, 6, 34513. | 3.3 | 46 |
| 22 | Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy. <i>Nature Communications</i> , 2018, 9, 4972. | 12.8 | 40 |
| 23 | In vivo imaging of retinoic acid receptor β transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. <i>Prostate</i> , 2005, 64, 20-28. | 2.3 | 37 |
| 24 | Functional regulation of hypoxia inducible factor-1 α by SET9 lysine methyltransferase. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 881-891. | 4.1 | 26 |
| 25 | Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 329-339. | 2.3 | 21 |
| 26 | Prostate Cancer-Associated Gene Expression Alterations Determined from Needle Biopsies. <i>Clinical Cancer Research</i> , 2009, 15, 3135-3142. | 7.0 | 15 |
| 27 | Carbohydrate-conjugated fluorescent silica nanoprobe for selective detection of galectin-1 and prostate cancer cells. <i>Science Letters Journal</i> , 2015, 4, . | 0.0 | 1 |
| 28 | Can Post-Transcription Modifiers Change the Course of Prostate Cancer?. <i>Translational Medicine Series</i> , 2006, , 179-194. | 0.0 | 0 |
| 29 | HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1 α -Inhibition. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 724059. | 3.7 | 0 |